217 related articles for article (PubMed ID: 22361600)
1. No evidence of "obesity paradox" after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry.
Akin I; Tölg R; Hochadel M; Bergmann MW; Khattab AA; Schneider S; Senges J; Kuck KH; Richardt G; Nienaber CA;
JACC Cardiovasc Interv; 2012 Feb; 5(2):162-9. PubMed ID: 22361600
[TBL] [Abstract][Full Text] [Related]
2. Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Ferenc M; Silber S; Sabin G; Tebbe U; Akin I; Hochadel M; Senges J; Kuck KH; Richardt G;
J Interv Cardiol; 2012 Aug; 25(4):344-52. PubMed ID: 22409587
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
Akin I; Bufe A; Eckardt L; Reinecke H; Richardt G; Kuck KH; Senges J; Schneider S; Nienaber CA;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):50-7. PubMed ID: 20578192
[TBL] [Abstract][Full Text] [Related]
6. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry).
Akin I; Bufe A; Eckardt L; Reinecke H; Senges J; Richardt G; Kuck KH; Schneider S; Nienaber CA;
Am J Cardiol; 2010 Nov; 106(9):1201-7. PubMed ID: 21029813
[TBL] [Abstract][Full Text] [Related]
8. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
10. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry.
Campo G; Saia F; Percoco G; Manari A; Santarelli A; Vignali L; Varani E; Benassi A; Sangiorgio P; Tarantino F; Magnavacchi P; De Palma R; Guastaroba P; Marzocchi A
Int J Cardiol; 2010 Apr; 140(2):154-60. PubMed ID: 19056134
[TBL] [Abstract][Full Text] [Related]
12. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: complete 2-year follow-up of a two-center registry.
Park KW; Kang SH; Park KH; Choi DH; Lee HY; Kang HJ; Cho YS; Yeon TJ; Chung WY; Koo BK; Chae IH; Choi DJ; Oh BH; Park YB; Kim HS
Int J Cardiol; 2011 Aug; 151(1):89-95. PubMed ID: 20605240
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
[TBL] [Abstract][Full Text] [Related]
15. In-hospital and one year outcomes with drug-eluting versus bare metal stents in large native coronary arteries: a report from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
Gordon PC; Cohen DJ; Kleiman NS; Montgomery JA; Semder CA; Kennedy KF; Keyes MJ; Piana RN;
Catheter Cardiovasc Interv; 2013 Oct; 82(4):E356-64. PubMed ID: 22511502
[TBL] [Abstract][Full Text] [Related]
16. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
[TBL] [Abstract][Full Text] [Related]
17. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
[TBL] [Abstract][Full Text] [Related]
18. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
Hannan EL; Racz M; Walford G; Holmes DR; Jones RH; Sharma S; Katz S; King SB
JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
[TBL] [Abstract][Full Text] [Related]
20. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
